secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2026-05-15T12:03:20+00:00
Accession:  0001193125-26-225369
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Q1 cash $9.5M, net loss $2.7M; initiates randomized Phase 2 for agenT-797 in ARDS
--------------------------------------------------------------------------------

- Cash $9.5M at Mar 31 (down from $13.4M at Dec 31); repaid $5.2M Agenus convertible note.
- Net loss $2.7M ($0.57/sh) vs $2.8M ($0.70/sh) year ago; raised $3.0M via ATM in Q1.
- Initiated randomized Phase 2 trial of agenT-797 in severe acute lung injury/ARDS; data expected H2 2026.
- Non-dilutive C-Further collaboration provides up to $1.1M for PRAME-targeted iNKT therapy in pediatric cancers.
- Upcoming ATS presentation May 20 on agenT-797 for coccidioides infection; NIH-funded GvHD program ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000119312526225369/0001193125-26-225369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000119312526225369/inkt-20260515.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-225369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer